Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Targeted therapies

Remembrance of things past — discontinuation of second-generation TKI therapy for CML

Data from the recent Stop 2G-TKI study confirm that around 60% of patients with chronic myeloid leukaemia who discontinue second-generation BCR–ABL1 tyrosine-kinase inhibitor (TKI) therapy after a sustained deep molecular response remain in remission for longer than 1 year. Importantly, the interim findings suggest that prior response to first-line TKI treatment might predict relapse risk after treatment discontinuation.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Baccarani, M. et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122, 872–884 (2013).

    Article  CAS  Google Scholar 

  2. Mahon, F. X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11, 1029–1035 (2010).

    Article  CAS  Google Scholar 

  3. Rousselot, P. et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J. Clin. Oncol. 32, 424–430 (2014).

    Article  CAS  Google Scholar 

  4. Rea, D. et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood http://dx.doi.org/10.1182/blood-2016-09-742205 (2016).

  5. Ross, D. M. et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122, 515–522 (2013).

    Article  CAS  Google Scholar 

  6. Hochhaus, A. et al. Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib: results from the ENESTFreedom study [abstract]. J. Clin. Oncol. 34, 7001 (2016).

    Article  Google Scholar 

  7. Hughes, T. P. et al. Treatment-free remission in patients with chronic myeloid leukemia in chronic phase according to reasons for switching from imatinib to nilotinib: subgroup analysis from ENESTop [abstract]. Blood 128, 792 (2016).

    Article  Google Scholar 

  8. Shah, N. P. et al. Treatment-free remission (TFR) in patients with chronic phase chronic myeloid leukemia (CML-CP) and in stable deep molecular response (DMR) to dasatinib — the DASfree Study [abstract]. Blood 128, 1895 (2016).

    Google Scholar 

  9. Imagawa, J. et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2, e528–e535 (2015).

    Article  Google Scholar 

  10. Ross, D. M. et al. Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features. Haematologica 96, 1720–1722 (2011).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Timothy P. Hughes.

Ethics declarations

Competing interests

T.P.H. and D.M.R. declare that they have received research funding and honoraria from Ariad, Bristol-Myers Squibb, and Novartis.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hughes, T., Ross, D. Remembrance of things past — discontinuation of second-generation TKI therapy for CML. Nat Rev Clin Oncol 14, 201–202 (2017). https://doi.org/10.1038/nrclinonc.2017.11

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2017.11

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer